COPB2 and central nervous system cancer: In addition, a retrospective cohort study found that COPB2 overexpression is significantly correlated with poor prognosis in patients with various types of cancers, including lung adenocarcinoma, hepatocellular carcinoma, and glioma; consequently, it was proposed as a possible prognostic and theranostic marker for cancer patients [2,10,11].